ArticleAntimicrobial agents and chemotherapy2016
A Novel Genome-Editing Platform for Drug-Resistant Acinetobacter baumannii Reveals an AdeR-Unrelated Tigecycline Resistance Mechanism.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- A non-antibiotic genetic selection system enables near-infrared in vivo imaging and evaluation of antibiotic efficacy for multidrug-resistant Acinetobacter baumannii.The Journal of antibiotics · 2026Article
- Carbohydrate competition by Enterobacteriaceae enhances colonization resistance to carbapenem-resistant hypervirulent K. pneumoniae.Microbiome · 2025Article
- Mutations in two-component signaling systems drive experimental evolution of tigecycline and colistin resistance inAntimicrobial agents and chemotherapy · 2025Article
- Targeting Acinetobacter baumannii resistance-nodulation-division efflux pump transcriptional regulators to combat antimicrobial resistance.npj antimicrobials and resistance · 2025Review
- Article
- The tigecycline resistance mechanisms in Gram-negative bacilli.Frontiers in cellular and infection microbiology · 2024Review
- An improved genome editing system for Sphingomonadaceae.Access microbiology · 2024Article
- Targeting virulence regulation to disarmVirulence · 2022Article
- A high-efficiency scar-free genome-editing toolkit for Acinetobacter baumannii.The Journal of antimicrobial chemotherapy · 2022Article
- An Unprecedented Tolerance to Deletion of the Periplasmic Chaperones SurA, Skp, and DegP in the Nosocomial Pathogen Acinetobacter baumannii.Journal of bacteriology · 2022Article
- Fitness Costs of Tigecycline Resistance inAntibiotics (Basel, Switzerland) · 2022Article
- Effects of Inactivation of d,d-Transpeptidases of Acinetobacter baumannii on Bacterial Growth and Susceptibility to β-Lactam Antibiotics.Antimicrobial agents and chemotherapy · 2022Article
- Novel tigecycline resistance mechanisms inEmerging microbes & infections · 2021Article
- A Transposon-Associated CRISPR/Cas9 System Specifically Eliminates both Chromosomal and Plasmid-BorneAntimicrobial agents and chemotherapy · 2021Article
- Characteristics and diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with drug-resistant clinical isolates of Acinetobacter baumannii.Antimicrobial resistance and infection control · 2021Article
- The Role of OmpR in Bile Tolerance and Pathogenesis of Adherent-InvasiveFrontiers in microbiology · 2021Article
- In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.The Journal of antimicrobial chemotherapy · 2020Article
- Scarless Removal of Large Resistance Island AbaR Results in Antibiotic Susceptibility and Increased Natural Transformability in Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2020Article
- A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii.Nature microbiology · 2020Article
- Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting.Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections with the Gram-negative coccobacillus Acinetobacter baumannii are a major threat in hospital settings. The progressing emergence of multidrug-resistant clinical strains significantly reduces the treatment options for clinicians to fight A. baumannii infections. The current lack of robust methods to genetically manipulate drug-resistant A. baumannii isolates impedes research on resistance and virulence mechanisms in clinically relevant strains. In this study, we developed a highly efficient and versatile genome-editing platform enabling the markerless modification of the genome of A. baumannii clinical and laboratory strains, regardless of their resistance profiles. We applied this method for the deletion of AdeR, a transcription factor that regulates the expression of the AdeABC efflux pump in tigecycline-resistant A. baumannii, to evaluate its function as a putative drug target. Loss of adeR reduced the MIC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.